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Abstract
This second part of practical Guidelines related to Kawasaki disease (KD) has the goal of contributing to prompt
diagnosis and most appropriate treatment of KD resistant forms and cardiovascular complications, including non-
pharmacologic treatments, follow-up, lifestyle and prevention of cardiovascular risks in the long-term through a set
of 17 recommendations.
Guidelines, however, should not be considered a norm that limits the treatment options of pediatricians and
practitioners, as treatment modalities other than those recommended may be required as a result of peculiar
medical circumstances, patient’s condition, and disease severity or individual complications.
Keywords: Kawasaki disease, Coronary artery abnormalities, Intravenous immunoglobulin, Aspirin, Personalized
medicine, Innovative biotechnologies, Child
Background
In 2008 the first Italian Kawasaki disease (KD) Guide-
lines were published. During the subsequent years new
data have been collected and updated treatment reports
have been published.
Kawasaki: Linee Guida italiane.
Scope
Scope of these revised Guidelines is to update evidence
on the following topics:
 efficacy of therapy in the chronic phase of the illness
and in its sequelae;
 short- and long-term follow-up;
 lifestyle and prevention of cardiovascular risks.
Users
These Guidelines are directed to pediatricians who work
in hospital, family pediatricians, and general practi-
tioners who work with children affected by KD and for
families of KD patients.
Note for users
The clinical management of each KD patient requires
the application of these recommendations based on the
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peculiar patient’s condition. We are pleased to publish
updated diagnostic and therapeutic indications for both
medical and paramedical staff as well as the most accur-
ate information for families.
Sponsorships
No person who participated in the drafting of these
Guidelines has been sponsored.
Dissemination
The text has been initially discussed during the Consen-
sus Conference “Kawasaki Disease Italian Guidelines” in
Rome during September 2015. The same text has been
rediscussed in the 71st National Congress of the Italian
Society of Pediatrics in Rome during June 2015, and fi-
nally approved in the 73th National Congress of the
Italian Society of Pediatrics in Naples during June 2017.
Updates
Future updates are planned within the next five years, or
sooner, if the medical literature will reveal evidences
showing that these Guidelines have become obsolete.
Methods
Different experts in general pediatric medicine, cardiology,
infectious diseases, rheumatology, immuno-allergology,
dermatology, radiology, or biologists experts in cell oxida-
tive stress have participated in writing these Guidelines.
They have been supported by representatives of family as-
sociations. The team has been requested to systematically
analyze the present literature about KD to define the fol-
lowing evidences about efficacy of therapies in the chronic
phase and in its sequelae, and efficacy of short-term and
long-term follow-up for KD patients.
The basic document was the previous Italian KD
Guidelines, which were published in 2008 (Marchesi
A et al. Malattia di Kawasaki: Linee-Guida Italiane.
Prospettive in Pediatria. 2008;38:266–83). Additionally,
further references from the last 8 years were considered,
using PubMed and Cochrane databases.
The following key-words were used: “child”, “Kawasaki
disease or Kawasaki syndrome”, “coronary arteries
aneurysm and ectasia”, “echocardiography”, “multi-slide
computed tomography”, “angiography”, “intravenous im-
munoglobulin”, “aspirin”, “corticosteroids”, “biological
drugs”, “follow-up”, limiting the search to documents on
humans and written in English or Italian. Heterogeneity
of the available researches and their low number did not
allow to perform a meta-analysis of each item. The rec-
ommendations of these Guidelines are based on the best
evidences available. Stronger recommendations are
based on high scientific quality data or, alternatively, on
the consensus of experts. In the Evidence Based Medi-
cine clinical Guidelines provide evidence levels based on
the study design (Table 1) and reported effectiveness
(Table 2).
Introduction
Nine years have passed since the first announcement of
the Italian Guidelines for diagnosis and management of
Kawasaki disease (KD) in a national journal, but recently
many more data have become available in relationship
with this acute systemic vasculitis occurring in childhood
[1]. According to the 2012 “Revised International Chapel
Hill Consensus Conference Nomenclature of Vasculitides”
[2], KD involves small and medium-sized vessels in each
organ and apparatus. In general terms, we can consider
KD as a self-limited heterogeneous disease with unknown,
probably multi-factorial, etiology, which primarily affects
infants and children under 5 years of age [3, 4].
The most significant complications in KD are coronary
artery aneurysms (CAA), but their overall incidence has
been consistently reduced by prompt recognition of the
disease and treatment with intravenous immunoglobulin
(IVIG) within 10 days of fever onset [5–9]. Unfortu-
nately, patients who show an insufficient response to
IVIG are more prone to develop cardiac sequelae, such
as dilation or stenosis of coronary arteries, myocardial
infarction, and valvular lesions [10]. Diagnosis of KD is
merely clinic, based on the diagnostic clinical criteria
(shown in the Part I of these Guidelines). Actually, no
clinical findings or tests can be considered specific for
KD, and this circumstance makes diagnosis extremely
challenging.
Goal of the second part of these Guidelines is to rec-
ommend the best practice tools in the management of
complicated KD, based on the most actual scientific evi-
dence, and improve the overall prognosis of the disease.
These Guidelines have been created for pediatricians
working in hospital, family pediatricians, and general
practitioners or nurses managing children affected by
KD and for families of KD patients.
Complications of KD can be distinguished in:
- Resistant forms of Kawasaki disease;
- Cardiovascular complications of Kawasaki disease;
- Other systemic complications of Kawasaki disease;
- Recurrent forms of Kawasaki disease.
Table 1 Level (class) based on study design, defined as follows
class I meta-analyses or systematic reviews from
randomized controlled trials
class II single randomized controlled trials
class III nonrandomized controlled trials
class IV retrospective case-control studies
class V number of cases without control group
class VI opinions of committees of experts and authorities
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Resistant forms of Kawasaki disease
A resistant KD is defined by failure in the response to
initial therapy with IVIG [11]. Patients may have a per-
sistent or recrudescent fever (> 38 °C, axillary or rectal)
after 36 h since the end of IVIG infusion. This event oc-
curs in more than 10% of patients with KD [12, 13]. It is
believed that IVIG non-responsiveness might reflect the
severity of the underlying inflammation, explaining the
increased incidence of CAA in this subset of patients. It
would seem useful to stratify patients according to the
risk to develop IVIG resistance and subsequent risk of
developing CAA to undertake in those at higher risk a
more aggressive initial treatment. Initial attempts were
made by Asai and Kusakawa, followed by Iwasa, Harada
and more recently by Kobayashi, Egami and Sano [14].
These predictive models have considered multiple fac-
tors, such as patient’s age, sex, duration of disease, white
blood cell count, hematocrit, platelet count, C-reactive
protein, transaminases, total bilirubin, albumin, sodium,
but all models have shown a lower sensitivity in Western
populations than in Japanese patients [15]. Unfortu-
nately, there is currently no universally accepted scoring
system to predict IVIG non-responsiveness, and for the
Caucasian population there is no validated risk score yet.
Cardiovascular complications of Kawasaki disease
The most relevant complications in KD are represented
by CAA, and different remodeling phenomena will affect
their outcome. The coronary artery dilation may start as
ectasia, slight expansion (less than 5 mm in diameter),
moderate dilation (from 5 to less than 8 mm) up to giant
aneurysms (more than 8 mm in diameter).
As exposed in the Part I of these Guidelines, the con-
cept of z-score was introduced several years ago to com-
pare the coronary artery diameter to the body surface
area and measure the standard deviation from the aver-
age in Z units (SD, z-score), using specific nomograms
(www.parameterZ.com). This is recommended for the
right coronary, left anterior descending, left main coron-
ary arteries, and also for other vessels such as the aortic
ring and ascending aorta. An accurate measurement of
weight and particularly height is important to enable cal-
culation of an accurate body surface area. According to
the most updated data in the medical literature related
to KD, we define the absence of coronary artery
involvement if the z-score is < 2, the presence of coronary
artery dilation if the z-score is between 2 and 2.5, and
the presence of coronary artery aneurysm if the z-score
is ≥2.5. This standard deviation system should be used
in the initial diagnosis of CAA, when there is a suspicion
of KD or when the selection may be more “coarse”, to
avoid losing patients who may be at substantial risk in a
near future (Table 3). Conversely, size criteria might be
used in the follow-up of KD patients, particularly if lo-
calized coronary artery injuries have been found [16, 17].
The majority of CAA occurs in the proximal segments
and at the branch level. KD patients with normal coron-
ary arteries or with mild ectasia at 6 weeks since disease
onset have an overall good prognosis [6, 18, 19]. On the
contrary, patients with persistent aneurysms are at risk
of stenosis and/or thrombosis of the same arteries. Giant
coronary aneurysms do not revert to a normal morph-
ology. The repair of affected vessels occurs by wall re-
modeling without total “renstitutio ad integrum”, but
with progressive intimal hyperplasia and fibrosis, that
lead to stenotic changes of the coronary artery, with risk
of thrombosis, myocardial ischemia, and sometimes even
sudden death. Rarely new aneurysms appear later in pa-
tients with pre-existing aneurysms and, if this occurs,
they represent post-stenotic dilations. In rare cases aneu-
rysms can develop in the axillary or celiac arteries. Other
different cardiovascular complications may develop less
frequently in patients with acute KD, and include myo-
carditis, pericarditis or pericardial effusion with myoper-
icarditis, valvular insufficiency, and, rarely, cardiac
arrhythmias. A specific treatment may be required for
these manifestations as well as for cardiac dysfunction
or heart failure [20, 21].
Echocardiography remains the gold-standard to iden-
tify CAA during the acute phase of KD up to the first
6 weeks. However, computed tomography (CT) or mag-
netic resonance (MR) angiography can be required for
an accurate risk stratification via evaluation of the vascu-
lar system, especially in growing children (see Part I,
Chapter “Long-term” follow-up).
Other systemic complications of Kawasaki disease
Other systemic KD complications are represented by
anemia, hypoalbuminemia, electrolyte imbalance (espe-
cially hyponatremia), paralytic ileus, liver dysfunction,
Table 2 Classification (grade) based on effectiveness, defined as
follows
grade A highly recommended
grade B recommended
grade C recommended, but evidence is uncertain
grade D non recommended
grade E contraindicated
Table 3 Classification of coronary artery abnormalities in the
acute phase of Kawasaki disease and severity classification
No coronary artery involvement: z-score < 2
Dilation of the coronary artery: z-score > 2 to < 2.5 SD
Small aneurysm of the coronary artery: z-score≥ 2.5 to < 5 SD
Medium aneurysm of the coronary artery: z-score≥ 5 to < 10 SD
Giant aneurysm of the coronary artery: z-score≥ 10 SD
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cholecystitis, seizures, diarrhea, vomiting, dehydration,
and heart failure, even iatrogenic from IVIG
infusion-related overload. Specific treatments are re-
quired for these complications. The exact cause of the
severe hypotension in these patients is unknown, though
probably due to several factors, i.e. inflammatory capillary
leak, myocardial dysfunction and imbalance of cytokines.
The occurrence of macrophage activation syndrome
(MAS) has also been reported in KD, heralded by
non-remitting fever, impaired liver function, hypofibrino-
genemia, hypertriglyceridemia, hyperferritinemia, pan-
cytopenia and frequently hemophagocytosis, that can be
observed in bone marrow fine needle aspiration [22, 23].
Some authors have reported the presence of clinical symp-
toms and laboratory abnormalities compatible with MAS
in 1.1% of KD patients if using the Ravelli’s diagnostic cri-
teria and in 0.42% if using the 2009 hemophagocytic lym-
phohistiocytosis diagnostic criteria [24, 25]. Another
complication is KD shock syndrome (KDSS), with similar
symptoms to MAS, but with higher incidence, which was
described by Kanegaye et al. in 2009 [26]: this disorder is
associated with severely increased inflammatory markers,
platelet consumption and increased risk of CAA, mitral
regurgitation and prolonged myocardial dysfunction. In
addition, patients with KDSS may be resistant to treat-
ment with IVIG and may need additional
anti-inflammatory treatments.
Recurrent forms of Kawasaki disease
Recurrence of KD ranges from 1.4 to 3% (respectively
from the Chinese and Japanese epidemiologic collec-
tion of studies available). Often KD symptoms are the
same as for the first episode. A longlasting fever,
IVIG resistance, elevated AST level, and reduced
hemoglobin are all risk factors significantly associated
with KD recurrence [27]. A recurring KD, sometimes
incomplete and atypical, may be associated with
higher incidence of CAA. Autoinflammatory syn-
dromes should be considered for a comprehensive
differential diagnosis in children with recurrence of
KD [28, 29].
Treatment of resistant forms of Kawasaki disease
Several second-line treatment options are available
in the resistant KD, represented by additional IVIG
infusions, intravenous methylprednisolone pulses,
infliximab, ulinastatin, cyclosporine A, methotrexate,
and plasmapheresis. Clinical trials for anakinra or
canakinumab are ongoing. Randomized controlled
trials that evaluated the effectiveness of different
drugs apart from the second infusion of IVIG are
few.
Corticosteroids
Corticosteroids are usually administered in all vasculitides
due to their immunosuppressive and anti-inflammatory
effect, with the aim of blocking the potential risk of CAA
in KD. Their use as first and second-line treatment is de-
bated, because of the differences regarding the selection of
patients (all patients versus high-risk patients) and the
ethnicity (Caucasian versus Eastern populations) reported
in different studies.
Methylprednisolone
Rational The intravenous pulses of methylprednisolone
have a quick immunosuppressive effect by blocking the
inflammatory cytokines and give a lower risk of imbal-
ance in electrolytes.
Indications Intravenous pulses of methylprednisolone
are indicated for patients with resistance to IVIG on the
basis of symptoms and laboratory tests, and for patients
resistant to IVIG after a first-line therapy. Intravenous
pulses of methylprednisolone are off-label in KD.
Dosage A single intravenous pulse of methylpredniso-
lone at the dose of 30 mg/kg of body weight can be pro-
vided in combination with IVIG as a first-line treatment
of high-risk KD patients; pulses can be provided for
3 days in the resistant cases.
Low-risk KD patients resistant to two previous infu-
sions of IVIG can receive pulses of methylprednisolone
(30 mg/kg/day) for 3 days.
Effectiveness There is no evidence that a first-line treat-
ment with IVIG combined with an intravenous pulse of
methylprednisolone prevent CAA in all patients with
KD, but only in those suspected to be resistant to IVIG.
For IVIG-resistant KD patients the second-line treat-
ment with intravenous methylprednisolone reduces the
duration of fever, but the overall incidence of CAA re-
mains similar [30–34].
Side effects Intravenous methylprednisolone side effects
are bradycardia, hypertension, hyperglycemia, and
hypothermia. A close monitoring of vital signs, ECG,
and blood pressure is required during pulse [35].
Prednisone
Rational The main purpose of therapy with prednisone
is to exert its anti-inflammatory effect, solving the vascu-
litis and blocking the potential risk of CAA: it has a
more powerful action in comparison with cortisol, in-
hibits transcription of different inflammatory cytokine
genes, and promotes transcription of anti-inflammatory
cytokines and proteins.
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Indications Suspected IVIG-resistant patients on the
basis of symptoms and laboratory tests or patients resist-
ant to IVIG given as first-line therapy.
Dosage If used in combination with IVIG in the
first-line treatment the dose of prednisone is 2 mg/kg/
day given intravenously in three doses; after fever and
improvement of inflammatory markers prednisone can
be administered orally. When CRP is normalized, pred-
nisone can be continued for 5 days, then is reduced to
1 mg/kg/day in 2 doses for further 5 days, then at
0.5 mg/kg/day for further 5 days.
Effectiveness The efficacy should be acceptable for
high-risk patients, but different studies have shown
contradictory results [36–38].
(Initial treatment with IVIG and prednisone for sus-
pected IVIG-resistant KD: level of evidence class I, grade
B; second-line treatment with prednisone for
IVIG-resistant KD: level of evidence class III, grade B).
Side effects Shock, infection, Legg-Calvé-Perthes dis-
ease, gastrointestinal perforation or bleeding, diabetes,
cataracts, glaucoma, chorioretinopathy, pancreatitis,
congestive heart failure, liver failure, arrhythmia, adreno-
cortical insufficiency, osteoporosis, myopathy, throm-
bosis, increased intracranial pressure, and seizures. Its
use is contraindicated in patients with infections, heart
or kidney failure, and history of previous heart attack.
Biological drugs
Biologic agents are highly effective drugs targeting the
presumed key-steps in the immune system, namely
tumor necrosis factor (TNF)-α and interleukin (IL)-1,
that are the triggering molecules in the KD-related vas-
culitis. Because of the paucity of safety and efficacy data,
many considerations are derived from the experience
with anti-TNF or anti-IL-1 drugs on short series of
patients.
Infliximab
Rational The serum concentration of TNF-α is elevated
in patients with KD and many studies have reported a
correlation between KD severity and CAA [39]. Inflixi-
mab (IFX), a chimeric monoclonal antibody against
TNF-α, suppresses inflammation by blocking the action
of TNF-α only, reducing the levels of interleukin-6, CRP,
and TNF-α soluble receptor, reducing the severity of
vasculitis, as demonstrated in animal models [40–42].
IFX may cause the production of antibodies in patients
undergoing repeated doses, and lead to allergic reactions
or loss of efficacy.
Indications KD patients resistant to IVIG. IFX use is
off-label for KD.
Dosage Single intravenous dose of 5 mg/kg of body
weight in 200–500 ml of saline solution for at least 2 h.
IFX has a half-life of about 9.5 days, and it has not
been established a lower age limit for use. No absolute
safety studies are available for infants and newborns.
Effectiveness Many studies confirm IFX short-term effi-
cacy in both IVIG-resistant and corticosteroid-resistant
KD patients, and also its safety, in about 80% of cases
[43–52]. In particular, the incidence of CAA might be
reduced if infliximab is used within the 10th day of
disease.
(Level of evidence for patients resistant to IVIG: class
II, grade C).
Side effects There are few data available for pediatric
patients. Infusion-associated reactions, such as anaphyl-
axis, skin rashes, pruritus, headache, bronchospasm, and
angioedema can appear; symptoms of hypersensitivity
may occur even after 3 days, and include myalgia, fa-
tigue, arthralgia, face and hand edema, dysphagia, urti-
caria, and headache. Exacerbation of heart failure and
infectious diseases might be disclosed. Any ongoing in-
fectious disease, and especially tuberculosis is an abso-
lute contraindication to the use of IFX. Therefore, a
screening strategy with family history, interferon-gamma
release assays, and also chest X-ray might be useful to
rule out tuberculosis. IFX should also be avoided in car-
riers of hepatitis B or C virus patients because of a risk
of activation and acute exacerbation of chronic hepatitis.
In addition, IFX should be postponed in case of MMR
vaccination in the previous 2 months and V vaccination
in the past month. There are no data about the develop-
ment of malignant tumors.
Anakinra
Rational Anakinra is a recombinant IL-1 receptor an-
tagonist blocking the natural biological activity of IL-1,
by competitively inhibiting binding of IL-1 and its recep-
tor, and down-regulating many IL-1-mediated inflamma-
tory reactions [53]. Based on a hypothetical model of
KD as an autoinflammatory disease, it was assumed that
anakinra might exert an antinflammatory effect on sys-
temic and coronary artery inflammation in these patients
[54].
Indications KD patients resistant to IVIG. Anakinra use
is off-label for KD.
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Dosage The suggested daily dose is 4–8 mg/kg of body
weight for subcutaneously injections given for an overall
period of 15 days since KD onset.
Effectiveness There are only anecdotal reports about
using anakinra in children with KD.
(Levels of evidence for patients resistant to IVIG: class
V, grade C).
Side effects They might involve the gastrointestinal
tract (nausea, diarrhea, abdominal pain, hypertransa-
minasemia), respiratory system (upper respiratory in-
fections, sinusitis, influenza-like illness, rarely
pneumonia), or skin (bruising, urticarial-like lesions,
local infections). Pain, erythema, and inflammation
might often appear in the injection sites, usually
during the first 4 weeks of therapy, then reversible
within 1 or 2 weeks. Rare are allergic reactions,
including anaphylaxis. Frequent is the report of
neutropenia, moderate eosinophilia, or moderate
thrombocytopenia.
Canakinumab
Rational Canakinumab is a high-affinity human mono-
clonal antibody targeted at IL-1β, with no cross-reactivity
with other members of the IL-1 family, including IL-1α,
which has been authorized for the treatment of systemic
juvenile idiopathic arthritis and different hereditary auto-
inflammatory syndromes [55, 56].
Indications KD patients resistant to IVIG. Canakinumab
use is off-label for KD.
Dosage Single subcutaneous injection of 4 mg/kg for a
body weight less than or equal to 40 kg.
Effectiveness Clinical trials are currently in phase I to
test canakinumab as a potential treatment for different
disorders, such as chronic obstructive pulmonary dis-
ease, gout, and coronary heart disease.
(Level of evidence for KD patients resistant to IVIG:
Class V, grade C).
Side effects They can be of minor relevance: rhinitis,
nasopharyngitis, nausea, vomiting, diarrhea, dizziness,
headache, or a mild redness with swelling, warmth, or
itching at the injection site. Sometimes they can be se-
vere: allergic reactions (rash, hives, difficulty in breathing
or swallowing, asthma, oral allergy syndrome),
hemoptysis, and infections.
Other drugs which have been used in the
drug-resistant forms of KD are ulinastatin, cyclospor-
ine, and methotrexate. Table 4 summarizes mechan-
ism of action, indication, dosage, side effects, and the
levels of evidence for these drugs. However, the use
of ulinastatin, cyclosporine, and methotrexate is
off-label in KD.
In 2008 Onouchi et al. reported a gene responsible
for susceptibility to KD, inositol 1,4,5-triphosphate
3-kinase C (ITPKC), which suppresses the activity of
T cells and leads to oversecretion of multiple
Table 4 Other drugs used in the drug-resistant Kawasaki disease
Ulinastatin [93, 94] Cyclosporine A [95–97] Methotrexate [98]
Mechanism of action Inhibitor of human trypsin Inhibition of calcineurin and
increased activity of T cells
Folic acid antagonist, suppression
of lymphoproliferation
Indications Patients resistant to IVIG
(also as initial treatment
combined with IVIG and ASA in
high-risk patients)
Patients resistant to IVIG
(there are no studies in patients
< 4 months of life)
Patients resistant to IVIG
Dosage Optimal dosing in not yet
determined in children, though in
many studies
The dosage is 5000 U/kg for 3–6
times per day (maximum dose:
50000 U); it should be given in a
second vein or temporarily
suspending IVIG infusion (as it
becomes turbid in contact with
other drugs)
4 mg/kg/day in 2 doses per os; in
case of persistence of fever the
dosage can be increased to
5–8 mg/kg/day; administered
until CRP normalization or for
10–14 days
10 mg/m2/week per os,
administered until fever
disappears
Side effects Anaphylactic shock, liver
dysfunction, leukopenia, rash,







dysfunction, acute kidney failure
Level of evidence Class III, grade C
(First-line treatment with IVIG +
ASA: class II, grade B)
Class V, grade C Class V, grade C
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cytokines, if dysfunctional, suggesting that it may
make KD patients more prone to IVIG resistance and
development of CAA [57].
Plasmapheresis
Rational Plasmapheresis removes cytokines and chemo-
kines activated in KD directly from the bloodstream.
Indication KD patients resistant to IVIG.
Dosage The circulating plasma is replaced with albu-
min at 5%; the volume to replace corresponds to ap-
proximately 1–1.5 times the volume of circulating
plasma, calculated according to the formula: [weight
(kg)/13 × (1-Ht/100) × 1000] (Ht, hematocrit [in %]).
A larger vein (femoral, subclavian, or jugular) should
be used for albumin administration with a double
lumen catheter; simultaneously heparin is adminis-
tered at an intravenous bolus of 15–30 U/kg, then at
15–30 U/kg/hour.
Effectiveness There are no prospective randomized
studies to evaluate the efficacy of plasmapheresis in KD,
but few retrospective ones comparing plasmapheresis to
IVIG [58].
(Level of evidence: class V, grade C).
Side effects Hypotension, hypovolemic shock, urticaria,
anaphylactic reactions, hypocalcemia, nausea, vomiting,
or bleeding disorders.
As already explained in the Part I of these Guidelines,
we define KD high-risk patients those who are younger
than 12 months, show elevated CRP, elevated serum
aminotransferase, hypoalbuminemia, severe anemia at
disease onset and those who might display early devel-
opment of CAA, signs of macrophage activation syn-
drome or shock.
Recommendation 1.
Treatment of non-responder low-risk KD patients is a
second bolus of IVIG. Pulses of methylprednisolone
(30 mg/kg/day) for 3 consecutive days are suggested in
the case of no response.
(III - B)
Recommendation 2.
Treatment of non-responder high-risk KD patients
is a second bolus of IVIG + 3 pulses of methylpred-
nisolone (30 mg/kg/day for 3 consecutive days,
followed by prednisolone: 2 mg/kg/day), following
gradual reduction of prednisolone dose and its sus-




Biological drugs may be used in IVIG-refractory KD
patients.
(II - C)
Finally, we have summarized the therapeutic recom-
mendations for patients with KD, both low-risk and
high-risk ones (Figs. 1 and 2).
Treatment of the cardiovascular complications of
Kawasaki disease
Regression of CAA depends on the initial size of the
vascular dilation: about half of CAA resolves within a
few years. In particular, a pseudo-normalization of lu-
minal dimensions is observed within 1–2 years when
aneurysms are small-sized and within 5 years in 80%
of cases if medium-sized. Rarely giant aneurysms
show a tendency to regress. Because of the repair
process, however, a stenosis can occur in the incom-
ing or outgoing aneurysmal area, secondary to intimal
hyperplasia or thrombotic occlusion, with risk of
myocardial ischemia, heart attack, and unexpected
death [59]. Long-term therapy in KD patients with
CAA aims at prevention of cardiovascular sequelae,
reduction of both frequency and severity of heart at-
tacks, and improvement of patient’s quality of life
[60–62]. Such therapy depends on the severity and
extension of coronary artery involvement. In the ab-
sence of “evidence-based” studies, recommendations
have been drafted by pediatric retrospective studies,
case reports, and extrapolation from experiences in
adults.
Platelet activation is critical in all KD phases, there-
fore, in case of persistent CAA, a chronic use of anti-
platelet low-dose ASA (3–5 mg/kg/day) must be
provided, optionally associated with other antiplatelet
and/or anticoagulant and/or anti-angina drugs, ac-
cording to the size of aneurysms, flow characteristics,




Mechanism of action of clopidogrel is based on the
inhibition of platelet aggregation induced by ADP,
and antiplatelet action is usually achieved with low
doses of clopidogrel (0.2 mg/kg/day) in children aged
< 24 months. Unfortunately there are no data related
to children aged ≥25 months and the dose suggested is
1 mg/kg/day (the maximum adult dose is 75 mg/day). In
case of ASA allergy or varicella (either wild disease or vac-
cination against varicella) clopidogrel might be an al-
ternative to ASA [63]. Side effects of clopidogrel
include malaise, myalgia, headache, dizziness, gastro-
intestinal symptoms, rash, itching, thrombotic
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thrombocytopenic purpura, and bleeding tendency.
Clopidogrel is off-label in KD.
Anticoagulants
In KD patients anticoagulants are indicated in case of
medium and giant aneurysms and in cases complicated by
thrombosis. Warfarin is the most widely used drug. Both
in urgency and at the beginning of anticoagulant therapy
warfarin should be associated with intravenous continuous
infusion of heparin, administered at a full anticoagulant
dose (monitoring the PTT, targeted between 60 and 85″
and 1,5–2,5 times the normal) for at least 48 h and in any
case until reaching a steady INR between 2 and 2.5 to
avoid the paradoxical thrombosis caused by the depletion
Fig. 2 Treatment of high-risk KD patients
Fig. 1 Treatment of low-risk KD patients
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of protein C and S, induced by early therapy with warfarin;
then heparin should be suspended. It is recommended to
pay attention to the bleeding tendency induced by these
drugs. Although no large-scale studies exist, related to the
use of heparin and low molecular weight heparin
(LMWH) in KD, their use can be considered both in in-
fants, for whom INR examination is not easy, and in case
of reintroduction of warfarin after eventual suspension
(due to eventual surgery). However, subcutaneous injec-
tions are required twice a day. Particularly, enoxaparin is a
LMWH with demonstrated safety and efficacy, frequently
used in the pediatric age [64]. Fondaparinux, a new
LMWH with a longer half-life, might be used in selected
cases (Table 5).
New oral anticoagulants
The new oral anticoagulants (e.g. dabigatran, rivaroxa-
ban, apixaban) show the advantage of having a predict-
able clinical effect without requiring routine laboratory
check, though they are off-label in the pediatric age and
do not currently have a clear indication in KD.
Recommendation 4.
Anti-platelet prophylaxis must be based on low-dose
ASA (3–5 mg/kg/day) associated with clopidogrel
(0.2 mg/kg/day in patients aged < 24 months or 1 mg/
kg/day if age ≥ 25 months, max 75 mg/day) in a single
dose for KD patients with medium-sized aneurysms
(≥5 mm and ≤ 7 mm or if z-score ≥ 7 and < 10) or in
those with multiple and complex aneurysms.
(VI - C)
Recommendation 5.
It is reasonable to treat KD patients with giant aneurysms
(≥8 mm), with or without stenosis, with low-dose ASA as-
sociated with warfarin (keeping INR targeted at 2.0–3.0).
(II-III - B)
Recommendation 6.
In infants or older children in whom warfarin is diffi-
cult to adjust, it is reasonable to treat giant aneurysms
with ASA and LMWH.
(VI - B)
Recommendation 7.
In KD patients with relevant and/or extraordinary risk
of thrombosis, e.g. those with giant aneurysms or a recent
coronary artery thrombosis, triple therapy with ASA, clo-
pidogrel, and warfarin or LMWH should be considered.
(VI - C)
Anti-angina drugs and coronary artery vasodilators
In KD patients younger than 2 years, symptoms of an-
gina are rare. The main purpose of the anti-angina ther-
apy is reducing heart rate and cardiac workload,
reducing pre- and afterload, and increasing the coronary
artery flow. Drugs of this group are beta-blockers, cal-
cium channel blockers and nitro-vasodilators (see
Table 6). Beta-blockers are the first-choice drugs for
stable exercise-induced angina, and in KD they may be
administered when a history of previous heart attack is
present both to prevent the reinfarction, and reduce
long-term mortality. The selective β-1 blockers are
Table 5 Anticoagulant drugs used in Kawasaki disease
Warfarin Non-fractionated heparin Low molecular weight heparin
(LMWH)
Mechanism of action Block of synthesis of vitamin
K-dependent coagulation
factors (II, VII, IX and X)
Bond with AT-III and inhibition of
II, VII, IX, X, XI, XII coagulation
factors
Bond with AT-III and inhibition of
II, VII, IX, X, XI, XII coagulation
factors
Therapeutic indications Medium to giant aneurysms, history
of heart attack, history of intra-
aneurysm thrombosis
Aneurysms with high thrombotic
risk, before starting therapy with
warfarin
Same as non-fractioned heparin
Dosage Initial dose of 0.05–0.12 mg/kg/day,
progressively increased over 4–
5 days to obtain an INR between 2.0
and 2.5
Initial intravenous dose: 50 U/kg
in 10 min or more, followed by
20–25 U/kg/hour to maintain
aPTT between 60 and 85″







diarrhea, hair loss, osteoporosis
Same as non-fractionated heparin,
but less osteoporosis
Interactions Reduced efficacy with chlorophyll
contained in green and yellow
vegetables (with high contents of
vitamin K), vitamin K-enriched milk,
phenobarbital, carbamazepine,
rifampicin; increased efficacy if
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recommended to avoid side effects in other organs.
Calcium channel blockers are the first-choice drugs
for angina, but their intravenous administration is
contraindicated in newborns and infants [17]. The use
of all the above-mentioned drugs is off-label in KD.
Statins
Hydroxymethylglutaryl coenzyme-A reductase inhibitors
(statins) are a cornerstone of therapy for the primary
and secondary prevention of atherosclerotic cardiovascu-
lar events in adults. They reduce low-density lipoprotein
cholesterol and have potentially beneficial pleiotropic ef-
fects on inflammation, endothelial function, oxidative
stress, platelet aggregation, coagulation, and fibrinolysis
[1]. Although controversy continues concerning whether
the vascular pathology of KD may lead to early athero-
sclerosis, statins could have a role in the long-term man-
agement of KD and an empirical low-dose treatment
may be considered for patients with past or current an-
eurysms, regardless of age or sex [1].
Treatment of coronary artery thrombosis
Patients with medium and giant aneurysms of coron-
ary arteries and those in whom the aneurysm sizes
rapidly increase over time are at greater risk of devel-
oping thrombosis and acute coronary syndrome. The
majority of acute heart attacks caused by a thrombus
in KD occurs within 2 years since disease onset. Cor-
onary thrombosis may occur more frequently within
the first 3 months of illness in these patients, with a
peak incidence between 15 and 45 days after onset. It
is therefore recommended to check frequently echo-
cardiography during this period. A heart attack in
childhood and in young children may be clinically si-
lent or it may be associated with sneaky and nonspe-
cific symptoms, such as unusual restlessness,
vomiting, or shock. A sudden deterioration of cardiac
function or a change in ECG findings should prompt
the suspicion of coronary thrombosis.
Actually, more and more patients with KD-related cor-
onary aneurysms reach adulthood, and this increases the
risk of heart attacks caused by thrombosis of the
aneurysm or progressive arterial stenosis caused by vas-
cular remodeling. The goal of treatment in KD patients
with coronary thrombosis is to restore the patency of
the flow, “preserve” the myocardial tissue, and increase
patient’s survival [65]. In the absence of randomized
controlled trials recommendations about therapy of cor-
onary thrombosis are derived from evidences in adult
population-related studies, despite the etiology of sten-
osis is different, and from small series of pediatric cases.
Recommendation 8.
Coronary artery thrombosis with actual or imminent oc-
clusion of the lumen should be treated with thrombolytic
therapy or with interventional cardiac catheterization.
(I - C)
Thrombolytic drugs
The most commonly administered thrombolytic therapy
is intravenous tissue plasminogen activator (tPA, alte-
plase) [66–68].
Tissue plasminogen activator
Mechanism of action Plasminogen activators are en-
zymes activating the conversion of plasminogen into
plasmin, which can promote clot lysis.
Therapeutic indications KD patients with acute heart
attack or intra-aneurysmal thrombi, and KD patients
with sudden extension of a thrombus in the coronary ar-
tery. Their use in KD patients is off-label.
Dosage For alteplase: 29.0–43.5 × 104 U/kg (administer-
ing 10% of the total dose over 1–2 min intravenously
and infusing the remainder over 60 min).
Effectiveness There are no data about the clinical effi-
cacy and safety of thrombolytic agents in children,
though we know that reperfusion following thrombolytic
therapy is usually reached by approximately 70–80% of
adult patients.
Recommendation 9.
Thrombolytic drugs have to be associated with
low-dose ASA and low-dose heparin with careful moni-
toring for the bleeding risk.
(I - C)
Recommendation 10.
In children tPA (alteplase) is the first-choice thrombo-
lytic drug, requiring to be associated with oral low-dose
ASA and intravenous heparin (10 U/kg/hour).
(VI - A)
Table 6 Long-term therapy for patients with coronary artery
aneurysms related to Kawasaki disease and anginal symptoms
Patients without anginal symptoms:
- patients without demonstrated ischemia: antiplatelet drugs
- patients with demonstrated ischemia: antiplatelet drugs + calcium
channel blockers. Evaluate revascularization, according to the pediatric
cardiologist’s opinion
Patients with anginal symptoms:
In addition to antiplatelet drugs:
- patients with exercise-induced angina: nitro-vasodilators and/or
calcium channel blockers
- patients with angina at rest or during sleep: calcium channel
blockers
- patients with angina in the night: calcium channel blockers +
nitro-vasodilators
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Other anti-platelet drugs
Less frequently, in the case of limited venous access,
subcutaneously injected LMWH might be used.
Considering the high risk of bleeding, unfractio-
nated heparin should be a second-choice drug.
Blood clotting test must be monitored daily, while
fibrinogen level should be maintained > 100 mg/dL,
and platelet count > 100.000/mm3 to minimize the
bleeding risk during treatment with unfractionated
heparin. In the case of significant thrombosis with
high risk of occlusion, a combination of low-dose
thrombolytic therapy may be also associated with a
platelet aggregation inhibitor, i.e. abciximab (glycopro-
tein IIb/IIIa inhibitor) infused intravenously as a bolus
of 0.25 mg/kg in 30 min, then followed by a continu-
ous infusion of 0.125 mg/kg/minute (max 10 μg/min)
for 12 h [69–71].
Recommendation 11.
Intravenous abciximab may be used as a bolus,
followed by a continuous infusion for 12 h, in case of
significant thrombosis with high risk of occlusion.
(VI - B)
Recommendation 12.
A small intracoronary mural thrombus “without im-
mediate threat of occlusion”, detected by echocardiog-
raphy in an early KD phase, may be treated with
intravenous abciximab (10 U/kg/hour).
(VI - B)
Non-pharmacological treatment of coronary
artery thrombosis
Invasive cardiologic procedures
Interventional catheterization procedures are limited
by the large delivery systems for small patients, high
risk of complications, and low efficacy, followed by
high risk of reintervention. Coronary artery reperfu-
sion both by invasive cardiologic interventional pro-
cedures and cardiac surgery can be considered after
an initial unsuccessful pharmacological thrombolysis.
Cardiologic procedures include percutaneous
thrombolysis, percutaneous angioplasty, and rota-
tional ablation [72–74]. CAA in KD are in general
terms more difficult to treat than those in adults,
and they often require that inflation pressure of the
ball is greater, with higher risk of causing new aneu-
rysms related to balloon dilation; the inflation pres-
sure recommended is ≤10 atm. The application of a
stent (“stenting”) is indicated in older children
(≥13 years of age) in whom the calcification of CAA
is relatively modest. The risk of development of new
aneurysms after balloon dilation is lower in patients
treated with the balloon dilation and stent compared
to those treated with only balloon dilation, but the
insufflation pressure of the ball should not be
greater than 14 atm. A rotablator may be required
to modify the shape of the lesion. Considering that
surgery is performed in patients between 13 and
18 years of age, it is imperative that pediatric cardi-
ologists share the clinical information with col-
leagues who will manage them into adulthood, for a
more efficient transition. In order to determine the
most appropriate interventional procedure it is desir-
able that physicians consider patient’s body size, cor-
onary angiography findings, and the use of
intravascular ultrasound (IVUS) [75].
Indications
- Patients with ischemic symptoms caused by
significant coronary artery stenosis (≥75% of the
luminal diameter).
- Patients in whom stenosis is significant (≥75% of the
luminal diameter) in the absence of ischemic
symptoms, but with instrumentally demonstrated
ischemia (stress ECG, stress perfusion imaging,
perfusion imaging stress).
Contraindications
- Patients with coronary ostial lesions.
- Patients with multi-vessel disease.
- Patients with significant coronary artery stenosis
(≥75% of the luminal diameter) or occlusion of the
contralateral coronary artery.
Recommendation 13.
First-choice cardiologic interventional treatment in pa-
tients with KD should be chosen on the experience of




Percutaneous coronary angioplasty is associated with
the risk of restenosis or occlusion in patients with
KD, requiring often the use of coronary stents or al-
ternative procedures, such as coronary artery bypass
grafting (CABG) or rotational ablation. For children
with persistent or progressive CAA who develop is-
chemic heart disease in early childhood a reliable op-
tion is represented by CABG using grafts from the
internal mammary artery [76, 77].
Indications
- Patients with severe occlusive lesions of the left
coronary artery.
- Patients with severe occlusive lesions in more [2 or 3]
vessels.
- Patients with severe occlusive lesions in the proximal
portion of the left anterior descending coronary artery.
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- Patients with a compromised collateral circulation.
- Patients with previous history of a heart attack (to
ensure secondary prevention of heart attacks).
In Japan the average age of children undergoing
CABG is between 5 and 12 years, though it can be
performed safely in younger children. The more fre-
quent used surgical CABG technique is graft of the
right or left thoracic mammary internal artery, which
ensures good long-term patency (equal to 87% in gen-
eral until 20 years). Other cardiac surgery associated
with CABG may be required for the reduction of
giant aneurysms in order to improve the coronary ar-
tery flow pattern and prevent the formation of
thrombi caused by the increase of the “shear stress”
on vessel walls [78, 79].
Heart transplantation
A dozen of KD cases has been reported worldwide
for heart transplantation, with an average age of
8.5 years, but also in subjects aged less than
4 months who experienced ventricular tachycardia or
fibrillation [80].
Indications
- Patients with a significant left ventricular dysfunction.
- Patients with potentially lethal arrhythmias.
- Patients with significant lesions in the peripheral
segments of the coronary arteries.
Follow-up of patients with Kawasaki disease
Short-term follow-up
Patients with KD must undergo a careful clinical moni-
toring of blood and instrumental exams in the
long-term, but cardiological evaluations with ECG and
echocardiography are crucial also in the short-term
follow-up.
Recommendation 14.
Cardiologic evaluation with ECG and echocardiog-
raphy should be performed at diagnosis of KD, to
highlight eventual early CAA, then should be re-
peated at 2, 4 and 8 weeks after disease onset in pa-
tients who do not have developed aneurysms. In
patients with CAA it is recommended to perform
echocardiography 2 times a week during the period
of rapid expansion of the dilation of coronary arter-
ies, and at least once a week in patients with giant
coronary aneurysms in the first 45 days after disease
onset.
(VI - B)
Cardiological evaluation performed on the second
month since disease onset allows to subdivide KD pa-
tients according to the cardiovascular impairment in dif-
ferent risk classes to establish a personalized follow-up.
It is important an accurate measurement of coronary ar-
tery diameters by the evaluation of the relative z-scores.
Long-term follow-up
Follow-up of KD patients must continue over time, espe-
cially for those who have presented CAA, considering
that it is not possible to exclude remote complications
even in the non-complicated cases. The aneurysmal le-
sions tend to regress (50–95%, according to case stud-
ies), mostly medium-sized and small-sized aneurysms.
Such regression may be due to myointimal proliferation
or thrombus organization and recanalization. Therefore,
it is extremely important a careful long-term follow-up
in KD patients with both persistent and regressed aneu-
rysms with different timing and mode.
The class stratification risk, related to the risk of
myocardial ischemia, established by the American
Heart Association (AHA), is a useful tool for a stan-
dardized management of KD patients with regard to
timing of controls, diagnostic tests, and therapeutic
indications [6, 8].
It should be noted that risk classes of each patient
with coronary artery impairment may vary over time
because of morphological changes in the coronary ar-
teries’ wall. The occurrence of thrombosis or stenosis
associated with CAA, in fact, increases the risk of
myocardial ischemia. Furthermore, the optimal
follow-up of patients with regressed aneurysms re-
mains still controversial since, even with the
normalization of vessel diameter, morphological and
functional alterations might persist. Indeed, the nor-
mal ultrasound coronary artery framework does not
necessarily coincide with the normal endothelial func-
tion. This justifies continuing seriated controls, al-
though less frequent, to trace the natural history of
the disease, also regarding the possible risk of athero-
sclerosis. It is reasonable to use echocardiographic
coronary artery luminal dimensions converted to body
surface area-adjusted z scores to determine risk strati-
fication of patients [81, 82]. Risk categories according
to the AHA are shown in Table 7. Different therapies




▪ Treatment with ASA for the first 8 weeks and in any
case until a documented normalization of both platelet
count and inflammatory markers.
▪ Cardiologic evaluations (ECG, echocardiogram,
monitoring of blood pressure) and any blood chemistry
tests with evaluation of lipid profile at 12 months since
disease onset.
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▪ No restriction of physical activity after the first
8 weeks.
CLASS II
▪ Treatment with ASA until normalization of both
platelet count and inflammatory markers and
disappearance of coronary artery lesions (also
tortuosity/stiffness of the vessel walls), documented by
two subsequent controls.
▪ Cardiologic evaluations (ECG, echocardiogram,
monitoring of blood pressure) and blood chemistry
tests with evaluation of lipid profile at 6 and 12 months
after disease onset.
▪ Clinical reassessment of the eventual cardiovascular
risk with physical activity counseling at 1 year since
disease onset.
▪ No restriction of the physical activity after the first
8 weeks.
CLASS III
▪ Treatment with ASA until complete regression of the
aneurysms documented by two subsequent negative controls.
▪ Cardiologic evaluations (ECG, echocardiogram,
monitoring of blood pressure) and blood chemistry
tests every 4–6 months, depending on the severity of
lesions. If there is a complete regression of aneurysms
documented by two subsequent negative controls,
cardiologic examinations (ECG, echocardiogram,
monitoring of blood pressure) annually in the first
3 years, then every 3–5 years (up to 18 years).
▪ Evaluation of myocardial perfusion every 2 years
above the age of 10 (stress-ECG and/or stress ECO)
with evaluation of the lipid profile.
▪ Coronary angiography or CT angiography if any
myocardial ischemia is highlighted.
▪ After the first 8 weeks physical activity without
restrictions (excluding athletic activities), guided by
myocardial perfusion assessment tests in patients over
10 years.
CLASS IV
▪ Antiplatelet treatment (ASA + possible association
with clopidogrel in selected patients) and any
anticoagulant (warfarin in the giant aneurysms or
LMWH in selected cases).
▪ Cardiologic evaluations (ECG, echocardiogram,
monitoring of blood pressure) and blood chemistry
tests every 4 months until a stable reduction of
aneurysms is documented by two successive negative
controls. Then, cardiology checks and blood tests
annually with annual assessment of myocardial
perfusion (stress ECG and/or stress echo or any stress
MRI with contrast).
▪ Coronary angiography or coronary CT angiography in
the first 6–12 months and thereafter when clinically
indicated.
▪ Physical activity based on annual myocardial
perfusion check; forbidden physical contact or collision
sports/games.
▪ Counseling for pregnancy in female patients on
anticoagulant treatment.
CLASS V
▪ Antiplatelet treatment (ASA + possible association
with clopidogrel in selected patients) and
anticoagulation with warfarin (or LMWH in selected
cases).
▪ Cardiologic evaluations every 3 months with ECG
and echocardiogram + possible Holter-ECG; annual as-
sessment of myocardial perfusion (stress ECG and/or
stress echo, stress MRI with contrast).
▪ Coronary angiography or coronary CT angiography
to guide treatment options and, in case of myocardial
ischemia, total body angio-CT.
▪ Coronary angiography or coronary CT angiography in
the first 6–12 months, and thereafter when clinically
indicated or suggested by non-invasive tests.
▪ Physical activity based on annual myocardial
perfusion evaluation; forbidden physical contact or
collision sports/games; avoid a sedentary lifestyle.
▪ Counseling for pregnancy in female patients on
anticoagulant treatment.
(VI - C)
Recommendations for a correct lifestyle and prevention
of cardiovascular risks
Cardiovascular sequelae caused by KD differ substan-
tially from the classic atherosclerosis from a pathological
point of view. The endothelial dysfunction and chronic
inflammatory reactions may occur even late in KD pa-
tients with giant or medium aneurysms, including those
Table 7 Cardiovascular risk classes in patients with Kawasaki
disease
Class I No abnormality of coronary arteries in the various
phases of the disease
Class II Transient coronary artery ectasia that disappears
within 8 weeks
Class III Single aneurysm of small-medium caliber between
+ 3 and + 7 SD in one or more arteries
Class IV One or more aneurysms ≥7 SD, including multiple
and complex giant aneurysms without any
obstruction
Class V Coronary artery obstruction at the angiography
Marchesi et al. Italian Journal of Pediatrics  (2018) 44:103 Page 13 of 18
which have regressed, causing intimal hyperplasia and
calcification if there is a localized stenosis. Although
endothelial dysfunction is a precursor of atherosclerosis
and autopsy studies seem to suggest that KD patients
may have more severe atherosclerotic lesions, it is still
unclear whether all KD patients have a higher risk for a
clear progression to atherosclerosis [83–85]. It is reason-
able to consider KD patients worthy of close monitoring
for cardiovascular risks, evaluating blood pressure, body
mass index, cholesterol, LDL, HDL, triglycerides, and pro-
moting correct lifestyles (for instance, avoid smoking) and
a regular physical activity with healthy eating [86, 87]. The
use of statins is still debated and their role in KD is yet to
clarify [88].
Recommendation 16.
Monitoring cardiovascular risk factors in KD patient
requires body mass index evaluation, blood pressure
control, and evaluation of the lipid profile (total choles-
terol, LDL, HDL, triglycerides).
(VI - B)
Fitness certification for patients with a previous Kawasaki
disease
Reference personnel for patients with a previous KD
who want to perform agonistic sports (competitive
sports or high-intensity activities) includes doctors
specialized in sports medicine who work in the
health systems or in authorized private structures;
certification for non-agonistic sports can be provided
by the family pediatrician and practitioner In KD pa-
tients the evaluation for fitness certification is compli-
cated by several reasons:
- there are non-subjective functional limitations (pa-
tients do not feel sick);
- cardiovascular risks depending on the coronary artery
damage is difficult to quantify, and patients affected by
giant aneurysms may show normal stress test when
myocardial perfusion is evaluated;
- few data are available to define exactly risks caused by
sport activity;
- it is difficult to correlate size of aneurysms to any
certification for fitness, though giant or multiple
aneurysms should be very carefully evaluated.
For the reasons above, specialized centres must certify
physical fitness through multi-disciplinary evaluations.
Activity restrictions depend on ongoing therapy (anti-
platelet or anticoagulant drugs). Pediatricians can assist
families in choosing which is the most appropriate sport.
Table 8 reports a classification of contact and collision
sports, showing limited contact or non-contact sports,
subdivided in high, mild, and less strenuous. Each pa-
tient on antiplatelet treatment must avoid contact and
collision sports, while patients on anticoagulant therapy
must also avoid limited contact sports [89].
Malattia di Kawasaki: Linee Guida italiane.
The following steps should be performed to certificate
fitness: family and personal history, clinical examination
and blood pressure control, resting 12-lead ECG, mono-
and 2D-colour Doppler echocardiogram, tapis roulant
stress test to determine stress tolerance, rhythm and
heart frequency, and possible myocardial ischemia. In
the presence of heart arrhythmias a dynamic 24 h-ECG
must be performed. If all these examinations are normal,
annual fitness certification can be produced for
non-agonistic activities [90–92].
Indications for physical activity in patients with a previous
Kawasaki disease
There are different indications for physical activity in
children who have presented KD, which can be stratified
according to various risk levels.
Recommendation 17.
Physical activity is recommended according to the fol-
lowing indications:
- risk level I e II: no restriction of physical activity
(non-agonistic) if clinical assessment and instrumental
tests are normal after 6–8 weeks.
Table 8 Sport classification according to the American Academy
of Pediatrics
Contact/collision Boxing, field hockey, ice hockey
American football
Motorcycle racing
Martial arts, rodeo, soccer, wrestling
Limited contact Baseball, basketball, bicycling, diving





Race walking, weight lifting




Non-contact Mildly strenuous Badminton
Curling
Table tennis
Non-contact Non strenuous Archery
Golf
Rifle range
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- risk level III: no restriction of physical activity (non-
agonistic) for children younger than 10–11 years after
6–8 weeks, then based on stress test each time a new
certification is required. In selected cases the evaluation
of myocardial perfusion might be indicated.
- risk level IV: physical activity is established on annual
stress test and evaluation of myocardial perfusion.
Contact/collision sports are not permitted because of
the risk of bleeding. A coronarography must be
performed if there is evidence of myocardial ischemia.
- risk level V: physical activity is established via six-
monthly stress test with at least annual evaluation of
the myocardial perfusion. Contact/collision sports are
not permitted because of the risk of bleeding. Agonistic






This second part of practical Guidelines related to
Kawasaki disease (KD) has the goal of contributing to
the most appropriate treatment of resistant forms and
KD-related cardiovascular/systemic complications,
follow-up, lifestyle and prevention of long-term risks
through a set of 17 recommendations.
These are based on the most actual scientific evidence,
and their aim is improving the overall prognosis of the
disease. We have refined the definition of resistant
forms, recurrent forms, cardiovascular and systemic
complications of KD. Concerning therapies, we have up-
dated treatment of resistant forms (especially with corti-
costeroids and biological drugs), of cardiovascular
complications (with anti-platelet and/or anticoagulants
drugs), and of coronary artery thrombosis (with both
pharmacological and non-pharmacological approaches).
Concerning follow-up of KD patients, we have analyzed
short- and long-term suggestions for the follow-up,
evaluating timing and type of different instrumental
techniques, according to each cardiovascular risk class,
introducing other advanced cardiovascular imaging
techniques (i.e. computed tomography or magnetic
resonance angiography). Although every clinical
decision-making should be individualized to the spe-
cific patient with KD, herein we have pointed up rec-
ommendations for a correct lifestyle and overall
prevention of cardiovascular risks, and finally we have
reassessed indications for physical activity in patients
with a previous KD.
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